General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Zentalis Pharmaceuticals in its US$165.2 Million Initial Public Offering

April 2, 2020
A New York and San Diego-based team led the clinical-stage biopharmaceutical company in the transaction.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, has announced the pricing of its initial public offering of 9,180,000 shares of common stock at a public offering price of US$18.00 per share, for total gross proceeds of approximately US$165.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on April 7, 2020, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 1,377,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. 

Latham & Watkins LLP represents Zentalis Pharmaceuticals in its initial public offering with a capital markets team led by New York partner Nathan Ajiashvili, and San Diego partners Cheston Larson, and Matthew Bush, with New York associates Salvatore Vanchieri, Matthew DeSilva, and Darby Dietrich.


    Related Capabilities